These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 33336224)

  • 21. Reducing the progression of Alzheimer's disease in Down syndrome patients with micro-dose lithium.
    Priebe GA; Kanzawa MM
    Med Hypotheses; 2020 Apr; 137():109573. PubMed ID: 31986471
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Detection of Brain Tau Pathology in Down Syndrome Using Plasma Biomarkers.
    Janelidze S; Christian BT; Price J; Laymon C; Schupf N; Klunk WE; Lott I; Silverman W; Rosas HD; Zaman S; Mapstone M; Lai F; Ances BM; Handen BL; Hansson O
    JAMA Neurol; 2022 Aug; 79(8):797-807. PubMed ID: 35789365
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterization of monomeric and soluble aggregated Aβ in Down's syndrome and Alzheimer's disease brains.
    Gkanatsiou E; Sahlin C; Portelius E; Johannesson M; Söderberg L; Fälting J; Basun H; Möller C; Odergren T; Zetterberg H; Blennow K; Lannfelt L; Brinkmalm G
    Neurosci Lett; 2021 May; 754():135894. PubMed ID: 33848613
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The AHEAD 3-45 Study: Design of a prevention trial for Alzheimer's disease.
    Rafii MS; Sperling RA; Donohue MC; Zhou J; Roberts C; Irizarry MC; Dhadda S; Sethuraman G; Kramer LD; Swanson CJ; Li D; Krause S; Rissman RA; Walter S; Raman R; Johnson KA; Aisen PS
    Alzheimers Dement; 2023 Apr; 19(4):1227-1233. PubMed ID: 35971310
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum MHPG strongly predicts conversion to Alzheimer's disease in behaviorally characterized subjects with Down syndrome.
    Dekker AD; Coppus AM; Vermeiren Y; Aerts T; van Duijn CM; Kremer BP; Naudé PJ; Van Dam D; De Deyn PP
    J Alzheimers Dis; 2015; 43(3):871-91. PubMed ID: 25125467
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Plasma and CSF biomarkers for the diagnosis of Alzheimer's disease in adults with Down syndrome: a cross-sectional study.
    Fortea J; Carmona-Iragui M; Benejam B; Fernández S; Videla L; Barroeta I; Alcolea D; Pegueroles J; Muñoz L; Belbin O; de Leon MJ; Maceski AM; Hirtz C; Clarimón J; Videla S; Delaby C; Lehmann S; Blesa R; Lleó A
    Lancet Neurol; 2018 Oct; 17(10):860-869. PubMed ID: 30172624
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alzheimer's Disease in the Down Syndrome: An Overview of Genetics and Molecular Aspects.
    Gomes FC; Mattos MF; Goloni-Bertollo EM; Pavarino ÉC
    Neurol India; 2021; 69(1):32-41. PubMed ID: 33642267
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plasma Neurofilament Light and Alzheimer's Disease Biomarkers in Down Syndrome: Results from the Down Syndrome Biomarker Initiative (DSBI).
    Rafii MS; Donohue MC; Matthews DC; Muranevici G; Ness S; O'Bryant SE; Rissman RA
    J Alzheimers Dis; 2019; 70(1):131-138. PubMed ID: 31156181
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Exploring Alzheimer molecular pathology in Down's syndrome cerebrospinal fluid.
    Portelius E; Soininen H; Andreasson U; Zetterberg H; Persson R; Karlsson G; Blennow K; Herukka SK; Mattsson N
    Neurodegener Dis; 2014; 14(2):98-106. PubMed ID: 24992945
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cerebrospinal fluid profile of NPTX2 supports role of Alzheimer's disease-related inhibitory circuit dysfunction in adults with Down syndrome.
    Belbin O; Xiao MF; Xu D; Carmona-Iragui M; Pegueroles J; Benejam B; Videla L; Fernández S; Barroeta I; Nuñez-Llaves R; Montal V; Vilaplana E; Altuna M; Clarimón J; Alcolea D; Blesa R; Lleó A; Worley PF; Fortea J
    Mol Neurodegener; 2020 Aug; 15(1):46. PubMed ID: 32807227
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Common genetic signatures of Alzheimer's disease in Down Syndrome.
    Sharma A; Chunduri A; Gopu A; Shatrowsky C; Crusio WE; Delprato A
    F1000Res; 2020; 9():1299. PubMed ID: 33633844
    [No Abstract]   [Full Text] [Related]  

  • 32. [Elucidating Pathogenic Mechanisms of Early-onset Alzheimer's Disease in Down Syndrome Patients].
    Asai M; Kawakubo T; Mori R; Iwata N
    Yakugaku Zasshi; 2017; 137(7):801-805. PubMed ID: 28674290
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neuronal exosomes reveal Alzheimer's disease biomarkers in Down syndrome.
    Hamlett ED; Goetzl EJ; Ledreux A; Vasilevko V; Boger HA; LaRosa A; Clark D; Carroll SL; Carmona-Iragui M; Fortea J; Mufson EJ; Sabbagh M; Mohammed AH; Hartley D; Doran E; Lott IT; Granholm AC
    Alzheimers Dement; 2017 May; 13(5):541-549. PubMed ID: 27755974
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Plasma amyloid and tau as dementia biomarkers in Down syndrome: Systematic review and meta-analyses.
    Alhajraf F; Ness D; Hye A; Strydom A
    Dev Neurobiol; 2019 Jul; 79(7):684-698. PubMed ID: 31389176
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Longitudinal telomere shortening and early Alzheimer's disease progression in adults with down syndrome.
    Jenkins EC; Marchi EJ; Velinov MT; Ye L; Krinsky-McHale SJ; Zigman WB; Schupf N; Silverman WP
    Am J Med Genet B Neuropsychiatr Genet; 2017 Dec; 174(8):772-778. PubMed ID: 28856789
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synaptophysin and synaptojanin-1 in Down syndrome are differentially affected by Alzheimer's disease.
    Martin SB; Dowling AL; Lianekhammy J; Lott IT; Doran E; Murphy MP; Beckett TL; Schmitt FA; Head E
    J Alzheimers Dis; 2014; 42(3):767-75. PubMed ID: 24927707
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cognitive decline and dementia in Down syndrome.
    Hithersay R; Hamburg S; Knight B; Strydom A
    Curr Opin Psychiatry; 2017 Mar; 30(2):102-107. PubMed ID: 28009725
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Alzheimer-Related Cerebrovascular Disease in Down Syndrome.
    Lao PJ; Gutierrez J; Keator D; Rizvi B; Banerjee A; Igwe KC; Laing KK; Sathishkumar M; Moni F; Andrews H; Krinsky-McHale S; Head E; Lee JH; Lai F; Yassa MA; Rosas HD; Silverman W; Lott IT; Schupf N; Brickman AM
    Ann Neurol; 2020 Dec; 88(6):1165-1177. PubMed ID: 32944999
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Behavioural and psychological symptoms of dementia in Down syndrome: Early indicators of clinical Alzheimer's disease?
    Dekker AD; Strydom A; Coppus AM; Nizetic D; Vermeiren Y; Naudé PJ; Van Dam D; Potier MC; Fortea J; De Deyn PP
    Cortex; 2015 Dec; 73():36-61. PubMed ID: 26343344
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The amyloid plaque proteome in early onset Alzheimer's disease and Down syndrome.
    Drummond E; Kavanagh T; Pires G; Marta-Ariza M; Kanshin E; Nayak S; Faustin A; Berdah V; Ueberheide B; Wisniewski T
    Acta Neuropathol Commun; 2022 Apr; 10(1):53. PubMed ID: 35418158
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.